Cargando…

Sex and age do not modify the association between glucocorticoids and bone mineral density in patients with rheumatoid arthritis: a cross-sectional study

BACKGROUND: It is unclear whether sex or age modify the association of glucocorticoid (GC) use with reduced bone mineral density (BMD) in patients with rheumatoid arthritis (RA). METHODS: We studied cross-sectional data of RA patients with current or previous GC treatment in a single center cohort s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palmowski, Andriko, Boyadzhieva, Zhivana, Nielsen, Sabrina M., Muche, Burkhard, Hermann, Sandra, Boers, Maarten, Bliddal, Henning, Christensen, Robin, Wiebe, Edgar, Buttgereit, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246103/ https://www.ncbi.nlm.nih.gov/pubmed/37287080 http://dx.doi.org/10.1186/s13075-023-03083-x

Ejemplares similares

No association between methotrexate and impaired bone mineral density in a cohort of patients with polymyalgia rheumatica, giant cell arteritis, granulomatosis with polyangiitis and other vasculitides—a cross-sectional analysis with dose–response analyses
por: Palmowski, Andriko, et al.
Publicado: (2023)

Glucocorticoids Are Not Associated with Bone Mineral Density in Patients with Polymyalgia Rheumatica, Giant Cell Arteritis and Other Vasculitides—Cross-Sectional Baseline Analysis of the Prospective Rh-GIOP Cohort
por: Palmowski, Andriko, et al.
Publicado: (2022)

Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease
por: Wiebe, Edgar, et al.
Publicado: (2022)

Reducing the Toxicity of Long-Term Glucocorticoid Treatment in Large Vessel Vasculitis
por: Palmowski, Andriko, et al.
Publicado: (2020)

Viewpoint: Glucocorticoids in the treatment of rheumatoid arthritis: points to (re)consider
por: Boers, Maarten
Publicado: (2023)

The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis
por: Cutolo, Maurizio, et al.
Publicado: (2014)

Glucocorticoids in rheumatoid arthritis: current status and future studies
por: Hua, Charlotte, et al.
Publicado: (2020)

Effectiveness and Safety of JAK Inhibitors in Autoinflammatory Diseases: A Systematic Review
por: Boyadzhieva, Zhivana, et al.
Publicado: (2022)

Observational studies on glucocorticoids are harmful!
por: Boers, Maarten
Publicado: (2017)

Acute murine antigen-induced arthritis is not affected by disruption of osteoblastic glucocorticoid signalling
por: Spies, Cornelia M, et al.
Publicado: (2014)

Anti-Inflammatory Effects of Low-Dose Glucocorticoids Compensate for Their Detrimental Effects on Bone Mineral Density in Patients with Rheumatoid Arthritis
por: Kim, Ji-Won, et al.
Publicado: (2021)

Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial
por: Hartman, Linda, et al.
Publicado: (2018)

Bone mineral density in patients with Juvenile Rheumatoid Arthritis
por: Zhizho, Ye, et al.
Publicado: (2008)

Possible role of lymphocytes in glucocorticoid-induced increase in trabecular bone mineral density
por: Grahnemo, Louise, et al.
Publicado: (2015)

Transgenic disruption of endogenous glucocorticoid signaling in osteoblasts does not alter long-term K/BxN serum transfer-induced arthritis
por: Maleitzke, Tazio, et al.
Publicado: (2023)

Assessment of Distal Radius Bone Mineral Density in Osteoporosis Patients Receiving Denosumab, Including Those with Rheumatoid Arthritis and Those Receiving Oral Glucocorticoids
por: Matsuno, Hiroaki
Publicado: (2016)

The impact of low-dose glucocorticoids on disease activity, bone mineral density, fragility fractures, and 10-year probability of fractures in patients with rheumatoid arthritis
por: Cheng, Tien-Tsai, et al.
Publicado: (2018)

The risk associated with spinal manipulation: an overview of reviews
por: Nielsen, Sabrina Mai, et al.
Publicado: (2017)

Smoking Cessation Rates among Patients with Rheumatoid Arthritis and Osteoarthritis Following the ‘Gold Standard Programme’ (GSP): A Prospective Analysis from the Danish Smoking Cessation Database
por: Laugesen, Monika, et al.
Publicado: (2022)

Can the painDETECT Questionnaire score and MRI help predict treatment outcome in rheumatoid arthritis: protocol for the Frederiksberg hospital's Rheumatoid Arthritis, pain assessment and Medical Evaluation (FRAME-cohort) study
por: Rifbjerg-Madsen, Signe, et al.
Publicado: (2014)

One-year effects of glucocorticoids on bone density: a meta-analysis in cohorts on high and low-dose therapy
por: Lems, Willem F, et al.
Publicado: (2016)

Altered molecular pathways and prognostic markers in active systemic juvenile idiopathic arthritis: Integrated bioinformatic analysis
por: Ren, Yi, et al.
Publicado: (2022)

Pain Sensitisation in Women with Active Rheumatoid Arthritis: A Comparative Cross-Sectional Study
por: Vladimirova, Nora, et al.
Publicado: (2015)

Effects of Denosumab on Bone Metabolic Markers and Bone Mineral Density in Patients Treated with Glucocorticoids
por: Sawamura, Masato, et al.
Publicado: (2017)

Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)
por: Buttgereit, Frank, et al.
Publicado: (2013)

Rheumatoid arthritis and risk factors for low bone mineral density
por: Arinoviche, R
Publicado: (2004)

Effect of research participation versus usual clinical care in patients with rheumatic and musculoskeletal disorders: a prospective cohort study
por: Ginnerup-Nielsen, Elisabeth, et al.
Publicado: (2023)

Paradoxically protective effect of glucocorticoids on bone mass and fragility fracture in a large cohort: a cross-sectional study
por: Bukhari, Marwan, et al.
Publicado: (2021)

Is Phytalgic(® )a goldmine for osteoarthritis patients or is there something fishy about this nutraceutical? A summary of findings and risk-of-bias assessment
por: Christensen, Robin, et al.
Publicado: (2010)

Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis
por: van Ouwerkerk, Lotte, et al.
Publicado: (2023)

The course of pain hypersensitivity according to painDETECT in patients with rheumatoid arthritis initiating treatment: results from the prospective FRAME-cohort study
por: Rifbjerg-Madsen, Signe, et al.
Publicado: (2018)

Glucocorticoid management in rheumatoid arthritis: morning or night low dose?
por: Paolino, Sabrina, et al.
Publicado: (2017)

Bodycomposition, bone mineral density and serum adipokines in juvenile idiopathic arthritis with previous glucocorticoid therapy
por: Markula-Patjas, Kati P, et al.
Publicado: (2014)

Glucocorticoid-Induced Bone Loss Is Associated with Abnormal Intravertebral Areal Bone Mineral Density Distribution
por: Manning, Louise I., et al.
Publicado: (2013)

Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia
por: Chandler, H., et al.
Publicado: (2019)

Glucocorticoids affect bone mineral density and bone remodelling in OVX sheep: A pilot study
por: Cabrera, Diana, et al.
Publicado: (2018)

Low bone mineral density can occur in children after shortterm systemic glucocorticoid treatment
por: Ahn, Moon Bae
Publicado: (2022)

Adherence to Methotrexate in Rheumatoid Arthritis: A Danish Nationwide Cohort Study
por: Bliddal, Henning, et al.
Publicado: (2015)

Bone Mineral Density Changes in Patients with Recent-Onset Rheumatoid Arthritis
por: Hafez, Eman A., et al.
Publicado: (2011)

Association Between Bone Mineral Density and Autoantibodies in Patients With Rheumatoid Arthritis
por: Amkreutz, Josephine A. M. P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_097okajuci5l3tapmg68iios9k